Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ziad Sawi

Anesthesiology Las Vegas, NV Medical Doctor

NPI 1194725127 CMS profile 995341

2320 Paseo Del Prado, B-207, Las Vegas, NV 89102

Open in the dashboard

General payments

$4,551

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ziad Sawi of Las Vegas, NV is reported in the CMS Open Payments database as having received $4,551 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $860 43
2024 General $957 36
2023 General $604 21
2022 General $618 27
2021 General $324 22
2020 General $420 30
2019 General $768 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziad Sawi
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Ziad Sawi were reported at $860. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Ziad Sawi Anesthesiology median Middle half National median
2019 $768 $72 $23–$151 $163
2020 $420 $36 $17–$120 $114
2021 $324 $49 $21–$135 $132
2022 $618 $52 $22–$144 $149
2023 $604 $53 $23–$143 $160
2024 $957 $55 $25–$150 $164
2025 $860 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Scilex Pharmaceuticals Inc. $990 76 payments
  2. Forte Bio-Pharma LLC $740 30 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $578 31 payments
  4. Nevro Corp. $282 2 payments
  5. Collegium Pharmaceutical, Inc. $267 14 payments
  6. Daiichi Sankyo Inc. $243 21 payments
  7. Medtronic USA, Inc. $195 9 payments
  8. Zyla Life Sciences $162 17 payments
  9. IBSA Pharma Inc. $153 7 payments
  10. Abbott Laboratories $152 1 payment
  11. Other $791 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,551 243 payments
  2. Gift $0 1 payment
Products named General payments · program years 2019–2025
  1. PROLATE Pain $733 29 payments
  2. PROLATE Pain $733 29 payments
  3. PROLATE Pain $733 29 payments
  4. NALOCET $733 29 payments
  5. ZTLido $729 54 payments
  6. RELISTOR Gastroenterology $509 27 payments
  7. PROLATE Pain $414 15 payments
  8. RELISTOR Gastroenterology $337 20 payments
  9. TANLOR $320 14 payments
  10. Morphabond ER $243 21 payments
  11. Other $2,510 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

3,150

Median for Anesthesiology: 322

Drug cost

$466,240

Median for Anesthesiology: $8,738

Branded share of claims

43.6%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 57 $128,757
Ztlido Lidocaine Brand 76 $72,399
Licart Diclofenac Epolamine Brand 47 $52,237
Diclofenac Sodium Generic 76 $46,240
Horizant Gabapentin Enacarbil Brand 23 $24,752
Roxybond Oxycodone Hcl Brand 11 $21,375
Movantik Naloxegol Oxalate Brand 49 $19,584
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 496 $14,788
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 380 $13,028
Lidocaine Generic 69 $12,016

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$95,136

Of which drugs: $1,372

Medicare patients

276

Average age 67

Services billed

3,406

179 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 42%
Depression 36%
Ischemic heart disease 32%
Chronic kidney disease 27%
COPD 22%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 45 114 $598
Injection, ketorolac tromethamine, per 15 mg J1885 Office 46 522 $262
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 30 $29
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 300 $27
Injection, magnesium sulfate, per 500 mg J3475 Office 11 57 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $253
$253 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $132
$132 76 —
NALOCET
  • Forte Bio-Pharma LLC $63
$63 — —
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $42
$42 11 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $38
$38 57 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record